The pharmacokinetics of cefpimizole (free acid equivalents of cefpimizole sodium), a broad-spectrum cephalosporin antibiotic, were evaluated after intramuscular administration of single doses (dose range, 100 to 1,000 mg) and multiple doses (dose range, 500 to 2,000 mg) given b.i.d. for 6 or 11 days. The kinetics after intramuscular administration correspond to a one-compartment model with first-order input. The Cefpimizole sodium (U-63,196E, AC-1370) (17) is a cephalosporin antibiotic with activity against a broad spectrum of gram-negative bacteria, including Pseudomonas aeruginosa. Cefpimizole (free acid equivalents of cefpimizole sodium) has been reported to have greater activity in vivo than in vitro (17), to inhibit many ampicillin-resistant bacteria and have stability against hydrolysis by chromosomal Plactamases (9), and to augment phagocyte function by human mnacrophages and neutrophils (11, 12) .
Cefpimizole sodium (U-63,196E, AC-1370) (17) is a cephalosporin antibiotic with activity against a broad spectrum of gram-negative bacteria, including Pseudomonas aeruginosa. Cefpimizole (free acid equivalents of cefpimizole sodium) has been reported to have greater activity in vivo than in vitro (17) , to inhibit many ampicillin-resistant bacteria and have stability against hydrolysis by chromosomal Plactamases (9) , and to augment phagocyte function by human mnacrophages and neutrophils (11, 12) .
The pharmacokinetics of cefpimizole (5) in humans receiving single-and multiple-dose intravenous (i.v.) infusions were evaluated and reported to be similar to those of other cephalosporins of this class. After i.v. administration, the drug is rapidly distributed and eliminated primarily through the kidneys with about 80% of the administered dose excreted in the urine as intact drug. The half-life of elimination, from either plasma or urinary excretion data, was 1.8 to 2.2 h. No apparent change in the distribution or elimination of cefpimizole was observed after multiple-dose i.v. regimens of 1, 2, and 4 g t.i.d. for 6 days, indicating that accumulation of the drug did not occur. Dose proportionality of cefpimizole was demonstrated for the plasma (area under the curve [AUC] ) and urine (cumulative urinary excretion) re- sults.
This report presents the results and pharmacokinetics of cefpimizole after single-and multiple-dose intramuscular (i.m.) administration to humans. The plasma and urine levels of parent drug were determined by liquid chromatographic (liquid chromatography-UV) methods reported earlier (6) . Pharmacokinetic evaluation of the data was accomplished, in part, by using NONLIN (7) . Statistical comparisons of the * Corresponding author. pharmacokinetic parameters were accomplished, in part, by using SAS analysis of variance procedures (13 Sample collection for multiple-dose studies. Blood and urine specimens were collected by the procedure described earlier (5) . For the first multiple-dose study, blood samples were collected after the first dose on days 1, 3, and 6 at 0 (predose), 0.5, 1.0, 1.5, 2.0, 3.0, 4.0, 6.0., and 12 h. Urine was also collected on days 1, 3, and 6 with the collection intervals being 0 to 2, 2 to 4, 4 to 8, 8 to 12, and 12 to 24 h. The 12-to 24-h collection represented the second dose for each day. The second multiple-dose study had blood collection times of 0 (predose), 0.5, 1.0, 3.0, 6.0, and 12 h after the first dose on days 1, 6, and 11. The urine collection intervals for days 1, 6, and 11 were the same as above for the first study.
Analytical methods. The plasma and urine specimens from the volunteers receiving i.m. doses of cefpimizole were analyzed for parent drug content by the liquid chromatography-UV (254 nm) methods reported earlier (6) . The methods were employed to assay for cefpimizole in plasma and urine after i.v. administration. A series of fortified plasma and urine samples and a number of duplicate samples were analyzed with each sample set to provide information on the accuracy and precision of the analytical methods. The results from the evaluations indicated that the methods were providing quantitative data for cefpimizole levels in plasma and urine specimens. The analytical methods had a quantification limit of 0.3 ptg/ml for plasma and 15 jxg/ml for urine. The absolute recovery of cefpimizole through the plasma sample preparation was 80 to 85% with a variation of less than 5% for an analysis set and with good linearity over the fortification series (1 to 20 ,ug/ml). For urine, the recovery of cefpimizole was quantitative. Precision of the plasma and urine analyses was good, with the duplicate analyses from each set having a variation of 1 to 5%.
Pharmacokinetic evaluation. The levels of cefpimizole in plasma and urine from the volunteers in the single-dose and multiple-dose i.m. studies were subjected to pharmacokinetic evaluation. The plasma levels were modeled with NONLIN (7) for a one-compartment model with first-order input and weighting the concentrations by the reciprocal squared (1/y2). The absorption (ka) and elimination (ke) rate constants and their half-lives were obtained. Other pharmacokinetic parameters determined included the area under the plasma curve from zero to ihfinity (AUCO), the apparent volume of distribution (Vd/F) where F is the fraction of the dose absorbed, the mean residence time (MRT), the concentration maximnum (Cmax), the cumulative urinary excretion (UT), and the pereent dose excreted in the urine (% dose). For the single-dose studies, the total body clearance (CL-'F) and renal clearance (CLR) were calculated. The equations for the various pharmacokinetic parameters were: (13) analysis of various procedures. These comparisons used the administered dose and the study to assess differences in the pharmacokinetic parameter averages.
RESULTS
The plasma and urine results for volunteers receiving single-dose i.m. administration of cefpimizole are shown graphically in Fig. 1 (Fig. 2) for the single- dose i.m. studies confirm the observations made from the plasma curves. The four dose groups of the first study had uniform cefpimizole urinary elimination. The second study had a lower cefpimizole total excretion and an apparent change in the elimination rate with the 0-to 2-h collection interval being lower in relation to the same time period for the first study. The urinary results from the last study are closer to thp data from the first study thap the second. The elimination of cefpimizole appeared to be slightly faster after the 1,000-mg i.m. dose, confirming the increased elimination phase of the plasma data ( Fig. 1) for this group.
The plas,ma and urine results from each individual of the six groups receiving single-dose i.m. cefpimizole were employed to calculate various pharmacokinetic parameters.
The average values and the standard deviations for each parameter for the groups are listed in Table 1 . The averages show no apparent change in VdIF, CLT/F, or CLR for the six doses, indicating similar distribution, total body elimination, or renal excretion of cefpimizole over the evaluated dose range. The pighest dose (1,000 mg) had a slight increase in ke and a corresponding decrease in MRT as was observed in Fig. 1 . The absorption rate, ka, varied substantially from subject to subject and from group to group. The limited number of plasma data points used to calculate ka prevented a good estimate for this parameter. Statistical evaluation of the single-dose pharmacokinetic parameters confirmed these observations. When the AUC, Cmax, and UT terms were normalized by dose, a statistical difference (P < 0.05) was observed for the three studies for all the parameters except CLR and VdIF (P > 0.1). When compared by dose, VdIF, AUC, CLT/F, ka, and ke were statistically different (P < 0.05), and MRT, Cmax, UT, and CLR were not different (P > 0.15). For those parameter averages that were different by dose, the 500-and 1,000-mg groups (studies 2 and 3) were different from the lower dose groups (study 1) for AUC, CLT/F, and ke while the difference in ka was observed for only the lowest dose group. Dose proportionality of cefpimizole after single-dose i.m. Fig. 3 (plasma) and Fig.  4 (cumulative urinary excretion). Blood and urine specimens were collected on three separate days during dosing; on days 1, 3, and 6 for the first study and on days 1, 6, and 11 for the second study. The average plasma values for each individual for each collection ti,me (Fig. 3) indicate that little or no change occurred after multiple i.m. doses. The peak plasma levels appear uniform for the three collections and proportional between dose groups. The elimination of cefpimizole also was uniform for the three collections and was parallel for the two dose groups of the first study. The highest dose group (second study) had a slightly faster elimination rate.
This dose group was the companion to the 1,000-mg dose group of the single-dose studies which also had a slight increase in the elimination rate. The average cumnulative urinary excretion (Fig. 4) collection days and appeared to be proportional for the three dose groups.
The plasma and urine results from each individual receiving multiple doses of cefpimizole were evaluated to determine the same pharmacokinetic parameters as for the singledose individuals. The pharmacokinetic parameter average values and standard deviations for the six subjects in each group and the three specimen collection days are listed in Table 2 . The last plasma time point was at or near the quantification level of the analytical method, and a good estimate of the elimination rate constant was obtained; thus, the AUC parameter was calculated from zero to infinity for the first dose to compare this term to the AUC obtained after the other doses. The dosage regimen was b.i.d.; the amount excreted was determined for 0 to 12 h, i.e., one dosing interval. The pharmacokinetic parameters showed excellent agreement, with the exception of ka, for the three collection days and between dose groups. The overall averages for the multiple-dose i.m. parameters VdIF, ke, MRT, CLT/F, and CLR had a relative standard deviation of less than 21%, indicating slight variation between subjects. Statistical evaluation of the various pharmacokinetic averages, after normalizing AUC, Cmax, and UT by dose, indicated that the kinetics were not statistically different (P > 0.04 for all terms) for the three dosing days. However, statistically significant differences (P < 0.05) were observed for AUC, MRT, UT, ka, and ke when compared by dose, with the 2,000-mg dose averages being different from the 500-and 1,000-mg dose values. The average values after multipledose i.m. administration were similar to the average values given in Table 1 in the various studies may have been caused by the injection technique employed to administer the drug, the amount of water intake by the volunteers, or the different times, individuals, and locations used for the studies.
The pharmacokinetics of cefpimizole after i.m. administration are similar to the kinetics of other broad-spectrum cephalosporin antibiotics given as i.m. doses. After a 500-mg i.m. dose, the Cma, of cefpimizole (15 to 20 jig/ml) was slightly less than the Cm,, reported for cefoperazone (25 ,ug/ml) (2, 14, 16) and moxalactam (25 ,.g/ml) (15, 16) ; slightly greater than the 12-to 14-,ug/ml Cmax cited for cefotaxime (14, 15) and for ceftizoxime (10) ; and about one-half the 45-to 50-,ug/ml Cma. reported for ceftriaxone (8) . The elimination-phase half-life of 1.8 to 2.1 for (4, 15) , the 1.3-to 1.8-h half-life for cefotaxime (1, 3) , and the 1.7-h half-line for ceftizoxime (10) , but less than the 5.4-h half-life reported for ceftriaxone (8) . The primary route of elimination for cefpimizole is renal with 70 to 80% of the administered i.m. dose excreted as parent compound in the urine. The level of cefpimizole in the urine is substantially higher than the reported level for ceftriaxone (25%) (8) , cefoperazone (20%) (2, 16) and cefotaxime (45 to 50%) (1, 16) and similar to the 75 to 85% urinary excretion cited for moxalactam (15, 16) and ceftizoxime (10) . The comparison of the pharmacokinetics of cefpimizole and other broad-spectrum cephalosporins after i.m. administration indicates that cefpimizole has peak plasma levels, elimination kinetics, and urinary excretion levels that are similar to those of other compounds of this class.
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